国证国际港股晨报-20250915

Core Insights - The report highlights the focus on the Federal Reserve's interest rate decision this week, with expectations of a potential rate cut [2][7] - The Hong Kong stock market showed a strong performance last week, with the Hang Seng Index rising by 1.16% and significant net inflows from southbound funds [2][4] Company Overview - The specific company under review is Jinfang Pharmaceutical-B (2595.HK), established in 2017, focusing on developing new treatment solutions for tumors and autoimmune diseases [9] - The company has a product pipeline with eight candidate products, five of which are in clinical development [9] Financial Performance - Projected revenues for Jinfang Pharmaceutical are 70 million RMB in 2023, 100 million RMB in 2024, and 80 million RMB by April 30, 2025, with net losses of 510 million RMB, 680 million RMB, and 70 million RMB respectively [9] Industry Status and Outlook - The global oncology drug market is expected to grow significantly, from $143.5 billion in 2019 to $253.3 billion by 2024, with a CAGR of 12.0%, and further to $596.7 billion by 2033 [10] - The Greater China oncology drug market is also expanding, projected to grow from $26.4 billion in 2019 to $35.9 billion by 2024, with a CAGR of 6.3% [10] Advantages and Opportunities - Jinfang Pharmaceutical's first approved KRAS G12C selective inhibitor presents a strong market potential due to its safety and efficacy [11] - The company is diversifying its pipeline with innovative RAS-targeted candidates and has a robust R&D platform [11] IPO Information - The IPO period for Jinfang Pharmaceutical is from September 11 to September 16, 2025, with trading commencing on September 19 [13] - The cornerstone investors have committed a total of $100 million, indicating strong backing for the IPO [14] Fundraising and Use of Proceeds - Approximately 71% of the raised funds will be allocated to the development of core products GFH925 and GFH375, while 19% will support other candidates, and 10% will be used for operational expenses [15] Investment Recommendation - Jinfang Pharmaceutical's core product GFH925 is the first of its kind in China and the third globally, with a market capitalization estimated at around 7 billion HKD at the IPO price of 20.39 HKD [17]